Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full year
Advancements across business units, R&D, and clinical development to support scale and international growth
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company“) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that its full year 2025 results, audited financial statements with management’s discussion and analysis have been filed.
“Throughout the year, we strengthened our leadership in cannabinoid-based medicine by advancing our research and development programs, progressing clinical initiatives, and deepening engagement with the Canadian medical community. We delivered the strongest financial performance in our history, reflecting operational discipline, optimization, and efficiencies.
“We also made targeted investments across our platforms to support commercial scalability, advanced product development, and enhanced the capabilities of the MyMedi.ca platform. These initiatives position Avicanna to scale efficiently, expand internationally, and unlock the full value of our business units and intellectual property globally,” stated Aras Azadian, CEO of Avicanna.
Earnings call: Management will host an earnings call and corporate update on Tuesday April 7th at 8:00 a.m. Eastern time. Presenters will include Aras Azadian, CEO, Nick Hillborn, Interim CFO and Dr. Karolina Urban, EVP, Medical Affairs. To register, follow the link: https://zoom.us/webinar/register/WN_RJACfyrPSo6CpVfSzcx5SQ
Financial Highlights:
- Revenue and Gross Profit: Revenue totaled $6.6 million in Q4 2025 and $25.48 million for the year ended December 31, 2025, consistent with $6.6 million and $25.46 million, respectively, in the prior year. Gross margin expanded to 53% in 2025 from 51% in 2024, driving gross profit to $13.4 million, compared to $12.9 million in the prior year. Margin expansion reflects continued optimization of product mix and cost efficiencies.
- Adjusted EBITDA: The Company generated positive adjusted EBITDA of $0.31 million in Q4 2025, compared to $(0.79) million in Q3 2025, reflecting improved operating leverage. For the year ended December 31, 2025, the Company achieved near break-even adjusted EBITDA with $(0.29) million, representing a 76% improvement compared to $(1.01) million in 2024. The year-over-year improvement was primarily attributable to higher gross margins and a 10% reduction in operating expenses.
Highlights and Advancements During 2025:
Canadian Commercial Advancements: During 2025 the Company further advanced its Canadian commercial platform across new SKUs, channels and listings. Additionally, the Company’s MyMedi.ca platform recovered from a modest Q1 performance of decreased sales, with three consecutive quarters of growth, combined with consistent increases in the proportion of sales attributed to Avicanna’s proprietary products. This resulted in 211,090 units of proprietary products sold during 2025, an increase of approximately 5% from 2024. At the end of the fourth quarter, the Company had 52 commercial SKUs and 174 commercial listings across medical and adult use channels, representing 27% growth in proprietary …